Bridgewater Associates LP Raises Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Bridgewater Associates LP boosted its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 11.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 112,999 shares of the specialty pharmaceutical company's stock after purchasing an additional 11,864 shares during the period. Bridgewater Associates LP owned about 0.19% of Jazz Pharmaceuticals worth $12,589,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of JAZZ. LSV Asset Management raised its position in shares of Jazz Pharmaceuticals by 4.2% during the second quarter. LSV Asset Management now owns 2,480,563 shares of the specialty pharmaceutical company's stock worth $264,750,000 after acquiring an additional 99,705 shares during the last quarter. Pacer Advisors Inc. raised its holdings in Jazz Pharmaceuticals by 15.3% during the 3rd quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company's stock worth $233,892,000 after purchasing an additional 278,465 shares during the last quarter. Baupost Group LLC MA raised its holdings in Jazz Pharmaceuticals by 52.8% during the 2nd quarter. Baupost Group LLC MA now owns 1,274,248 shares of the specialty pharmaceutical company's stock worth $136,000,000 after purchasing an additional 440,552 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Jazz Pharmaceuticals by 48.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,222,198 shares of the specialty pharmaceutical company's stock worth $130,447,000 after purchasing an additional 398,549 shares during the period. Finally, Swedbank AB bought a new stake in shares of Jazz Pharmaceuticals in the 2nd quarter valued at $106,936,000. 89.14% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on JAZZ shares. Royal Bank of Canada boosted their target price on shares of Jazz Pharmaceuticals from $175.00 to $179.00 and gave the company an "outperform" rating in a report on Wednesday, October 23rd. StockNews.com raised Jazz Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Thursday, August 1st. Needham & Company LLC reaffirmed a "buy" rating and set a $207.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, November 21st. HC Wainwright reissued a "buy" rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Finally, Robert W. Baird increased their target price on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an "outperform" rating in a research note on Monday, November 18th. Three investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $175.33.

Insider Activity

In other Jazz Pharmaceuticals news, SVP Mary Elizabeth Henderson sold 1,410 shares of the stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $108.30, for a total value of $152,703.00. Following the completion of the sale, the senior vice president now owns 14,531 shares in the company, valued at approximately $1,573,707.30. This trade represents a 8.85 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Neena M. Patil sold 3,700 shares of the business's stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $123.41, for a total value of $456,617.00. Following the completion of the transaction, the executive vice president now owns 33,048 shares in the company, valued at $4,078,453.68. The trade was a 10.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 6,110 shares of company stock worth $720,160 over the last 90 days. 4.20% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Stock Down 0.9 %

JAZZ stock traded down $1.05 during mid-day trading on Friday, reaching $121.59. 286,839 shares of the company traded hands, compared to its average volume of 675,459. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The firm's 50 day moving average price is $114.66 and its 200 day moving average price is $111.07. The stock has a market cap of $7.35 billion, a price-to-earnings ratio of 17.13, a P/E/G ratio of 1.03 and a beta of 0.57. Jazz Pharmaceuticals plc has a fifty-two week low of $99.06 and a fifty-two week high of $134.17.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.